CCL18 and bladder transitional cell carcinoma: In addition, CCR2/CCL2, CCR8/CCL1 and CCL18 are newly identified targets that alter the immunosuppressive microenvironment and improve the effect of immunotherapy in BLCA (Tao Wang et al., 2020; Tu et al., 2020).